Metastatic Neoplasm

Oncology
3
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

REVOLUTION Medicines
REVOLUTION MedicinesREDWOOD CITY, CA
1 program
1
VociprotafibPhase 1/2
Sanofi
SanofiPARIS, France
1 program
1
VociprotafibPhase 1/21 trial
Active Trials
NCT04418661Terminated65Est. Apr 2024
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-8294Phase 11 trial
Active Trials
NCT07030712Recruiting67Est. Aug 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SanofiVociprotafib
Merck & Co.MK-8294

Clinical Trials (2)

Total enrollment: 132 patients across 2 trials

NCT04418661SanofiVociprotafib

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Start: Jun 2020Est. completion: Apr 202465 patients
Phase 1/2Terminated

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Start: Jul 2025Est. completion: Aug 202767 patients
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 132 patients
3 companies competing in this space